U.S. Drug Innovation Share Falls to Low-30% Range as China Approaches 30%
The U.S. share of global innovative drug trials has declined from the mid-40% range a decade ago to the low-30% range, while China's share has climbed steadily toward 30%, narrowing the gap between the two countries in pharmaceutical R&D competition.
The U.S. share of global innovative drug trials has fallen from the mid-40% range a decade ago to the low-30% range, while China's share has climbed steadily toward 30%. The gap between the two countries has narrowed sharply, signaling rising competition in pharmaceutical research and development.
Leveraging advantages in efficiency, talent, and quality, China's innovative drug sector has grown into an indispensable force within the global pharmaceutical innovation system. In cutting-edge technology areas such as bispecific antibodies, antibody-drug conjugates (ADCs), and small nucleic acid therapeutics, China has established globally competitive R&D clusters that continue to drive robust cross-border deal activity.
In 2025, the global share of innovation-driven pharmaceutical transactions involving China exceeded 50% for the first time, with total transaction value reaching a historic high of US$135.7 billion. Despite this milestone, only about 5% of China's new drug pipelines have entered the transaction spotlight, leaving a wealth of high-value Chinese innovative drug assets yet to be discovered by global partners.
The shift in global pharmaceutical innovation reflects China's growing capabilities in advanced therapeutic modalities and its expanding role in international drug development partnerships.